Indivior Pharmaceuticals, Inc. (INDV)
Indivior Pharmaceuticals, Inc. (INDV) from its SEC filings: 2025 revenue $1.2 billion (+4% vs the year before), net margin 17%, free cash flow -$93.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $1.2 billion |
| Revenue growth | +4% |
| Net income | $210.0 million |
| Net margin | 16.9% |
| Free cash flow | -$93.0 million |
| Diluted EPS | $1.64 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +14% |
| Cash | $222.0 million |
| Long-term debt | $487.0 million |
| Share count, 1 year | -5% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.